Grace and Molecule.one partner to scale peptide building block synthesis with AI-driven automation
- Multi-year strategic agreement to accelerate synthesis and scale-up of peptide building blocks.
- Collaboration deploys Molecule.one’s MARIA™ platform to run AI analyses and thousands of microliter high-throughput reactions autonomously.
- Initial focus on peptide components for therapeutics, including GLP‑1 treatments for weight loss and diabetes, to address supply-chain bottlenecks.
- Market for metabolic-disease peptides is expected to more than double by 2030, surpassing $100 billion, highlighting urgent manufacturing demand.
Partnership scope
Grace and Molecule.one entered a multi-year strategic agreement to discover and deploy scalable manufacturing methods for chemical compounds, beginning with peptide building blocks. The collaboration aims to accelerate development timelines and strengthen capabilities at Grace’s U.S. fine chemicals manufacturing sites.
Technical approach
The effort pairs Molecule.one’s MARIA™ platform—AI-driven retrosynthesis coupled with a microliter automated laboratory—with Grace’s fine-chemicals expertise. MARIA™ will conduct AI analysis and autonomously run thousands of miniaturized reactions to identify and prioritize novel, efficient production routes and ensure reproducible lab results.
Target molecules and commercial context
The first phase targets peptide components used in therapeutics, including GLP‑1 treatments for weight loss and diabetes, where demand is strong. Conventional synthesis routes for peptide building blocks are often inefficient and hard to scale; the collaboration seeks scalable, reliable alternatives as the global market for metabolic-disease peptides is projected to exceed $100 billion by 2030.
Background
Molecule.one was the winner of the Standard Industries Chemical Innovation Challenge and its $1 million award for MARIA™. The partnership positions the companies to deploy AI-driven discovery and synthesis workflows from initial scaling through full production.
Source: Grace
